for people ages 18 years and up (full criteria)
at Orange, California
study started
completion around
Principal Investigator
by Farshid Dayyani



This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.

Official Title

Proof of Concept Study of ctDNA Guided Change in Treatment for Refractory Minimal Residual Disease in Colon Adenocarcinomas


Treatment on study will be administered in 14 day cycles.


Colon Adenocarcinoma, Colorectal Cancer, Adenocarcinoma, Residual Neoplasm, Colonic Neoplasms, Irinotecan, TAS-102, Signatera MRD ctDNA Assay, TASIRI


You can join if…

Open to people ages 18 years and up

  1. Patients must have histologically or cytologically confirmed adenocarcinoma of the colon (high rectal cancer is eligible if resected and no radiation needed). Other histologies which are treated per NCCN guidelines for adjuvant colon cancer are eligible.
  2. Must have Stage II, Stage III, or Stage IV colorectal cancer after curative intent resection eligible for adjuvant doublet chemotherapy for at least 3 months.
  3. Must have ctDNA positive assay (tested by Signatera MRD assay) after at least 3 months of perioperative chemotherapy
  4. Age ≥ 18 years
  5. Performance status: ECOG performance status ≤2
  6. Life expectancy of greater than 3 months
  7. Adequate organ and marrow function as defined below:
    1. leukocytesL ≥ 3,000/mcL
    2. absolute neutrophil count: ≥ 1,500/mcL
    3. platelets: ≥ 80,000/mcl
    4. total bilirubin: within normal institutional limits
    5. AST(SGOT)/ALT(SPGT): ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present
    6. creatinine: <1.5 X ULN
  8. The effects of TAS-102 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because topoisomerase inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
    1. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
    2. Has not undergone a hysterectomy or bilateral oophorectomy; or
    3. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  9. Ability to swallow tablets

    10. Ability to understand and the willingness to sign a written informed consent.

You CAN'T join if...

  1. Patients who have had major surgery within 4 weeks, or chemotherapy or radiotherapy within 2 weeks prior to Cycle 1 Day 1
  2. All toxicities attributed to prior anti-cancer therapy other than alopecia must have resolved to grade 1 or baseline
  3. Patients may not be receiving any other investigational agents.
  4. Patients with known metastases.
  5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102, irinotecan or other agents used in study.
  6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  7. Prior treatment with irinotecan or TAS-102.
  8. History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ.
  9. Inability to comply with study and follow-up procedures as judged by the Investigator

    10. Patients who are pregnant or nursing due to the potential for congenital abnormalities

    and the potential of this regimen to harm nursing infants. -


  • Chao Family Comprehensive Cancer Center, University of California, Irvine accepting new patients
    Orange California 92868 United States

Lead Scientist at UC Irvine

  • Farshid Dayyani
    Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 92 research publications


accepting new patients
Start Date
Completion Date
University of California, Irvine
Phase 1 research study
Study Type
Expecting 22 study participants
Last Updated